| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41366-019-0513-Y |
| P698 | PubMed publication ID | 31911662 |
| P2093 | author name string | Jianping Weng | |
| Fen Xu | |||
| Zonglan Chen | |||
| Huimin Gu | |||
| Huanyi Cao | |||
| Beisi Lin | |||
| Wanrong Guo | |||
| P2860 | cites work | Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist | Q60173685 |
| Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial | Q84342991 | ||
| Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice | Q24629441 | ||
| Pharmacology, physiology, and mechanisms of incretin hormone action | Q27021545 | ||
| Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase | Q28215845 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice | Q28510099 | ||
| Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice | Q34097903 | ||
| Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans | Q34099337 | ||
| Leptin resistance and obesity | Q34571659 | ||
| Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle | Q35053046 | ||
| Skeletal muscle membrane lipid composition is related to adiposity and insulin action | Q35768477 | ||
| Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | Q36465496 | ||
| Role of intramyocelluar lipids in human health | Q37007425 | ||
| Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome | Q37052532 | ||
| The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes | Q37765850 | ||
| The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review | Q37954675 | ||
| Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice | Q38304356 | ||
| Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor | Q38342748 | ||
| Intramuscular lipid content is increased in obesity and decreased by weight loss | Q39535127 | ||
| GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. | Q39961713 | ||
| Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription | Q42247586 | ||
| Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells. | Q42502081 | ||
| Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus | Q43014666 | ||
| One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress | Q43056507 | ||
| SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis | Q43412126 | ||
| Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). | Q43769439 | ||
| Mitochondrial capacity in skeletal muscle is not stimulated by weight loss despite increases in insulin action and decreases in intramyocellular lipid content | Q46770144 | ||
| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study | Q47956183 | ||
| SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress. | Q51036933 | ||
| Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. | Q51484711 | ||
| Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. | Q54095921 | ||
| Chronic leptin treatment stimulates lipid oxidation in immortalized and primary mouse skeletal muscle cells. | Q54778713 | ||
| Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. | Q55033199 | ||
| The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males | Q59326156 | ||
| Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice | Q59328728 | ||
| Leptin Directly Alters Lipid Partitioning in Skeletal Muscle | Q59515980 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 937-947 | |
| P577 | publication date | 2020-01-07 | |
| P1433 | published in | International Journal of Obesity | Q6051519 |
| P1476 | title | Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice | |
| P478 | volume | 44 |
Search more.